OSAKA, Japan & AUSTIN, Texas--( BUSINESS WIRE )--Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates’ engineered toxin bodies (ETB)
Combined Company Has a Unique Biological Platform with a Differentiated Mechanism of Action in Oncology and Two Clinical-Stage Candidates, MT-3724 and Evofosfamide Combined Company to Commence Trading on The Nasdaq Capital Market on August 2, 2017 under Ticker Symbol “MTEM” Approximately $75.0
